Osimertinib-induced radiation recall pneumonitis.
Jyothsna KuriakoseJenifer Jeba SundararajThangarathi CelineBarney IsaacManisha ManeAshish SinghBalukrishna SasidharanPublished in: BMJ supportive & palliative care (2023)
Radiation recall pneumonitis (RRP) is a type of radiation induced lung injury that develops in a previously irradiated lung field and is triggered by administration of chemotherapeutic or immunomodulating agents. To our knowledge there is only one report of Osimertinib induced RRP. The predominant symptoms include dyspnea and cough which usually resolve after stopping the inciting agent and with glucocorticoids. We describe a 52-year-old lady with lung cancer who developed Osimertinib induced RRP. She had significant dyspnoea and cough despite stopping Osimertinib and treatment with corticosteroids. She was referred to specialist palliative care team for alleviation of symptoms. Her symptoms responded well with non-pharmacological measures and pharmacological agents including opioids and mirtazapine. This is the first report on the effect of supportive care interventions on symptom relief in Osimertinib induced RRP.
Keyphrases
- palliative care
- small cell lung cancer
- radiation induced
- advanced non small cell lung cancer
- high glucose
- diabetic rats
- epidermal growth factor receptor
- drug induced
- radiation therapy
- oxidative stress
- physical activity
- advanced cancer
- pain management
- systemic sclerosis
- sleep quality
- combination therapy
- stress induced